RLYB

Rallybio Corp (RLYB) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Rallybio Corp is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases, primarily in complement dysregulation and hematology. The company is classified as an emerging growth company and a smaller reporting company. As of August 1, 2025, there were 41,786,471 shares of common stock outstanding.

Key Financial Metrics

Note: Revenue is derived from collaboration and license agreements, primarily with Johnson & Johnson. The company has no commercial product sales.

Material Changes vs. Prior Period

• Significant Expense Reduction: Net loss decreased by approximately 40% in Q2 2025 compared to Q2 2024 ($9.7M vs. $16.2M). This improvement is primarily driven by a $6.9M reduction in Research and Development (R&D) expenses.
• Program Discontinuation: In April 2025, the company discontinued the RLYB212 program for Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) after Phase 2 data failed to achieve target concentrations. This decision eliminated significant clinical and manufacturing costs associated with that program.
• Workforce Reduction: In May 2025, the company executed a workforce reduction eliminating approximately 40% of positions to focus resources on the lead program, RLYB116. This resulted in $1.7M in restructuring charges (severance) recognized in Q2 2025.
• Liquidity Position: Total cash, cash equivalents, and marketable securities decreased from $68.3M at year-end 2024 to $45.7M at June 30, 2025, reflecting a net cash burn of $18.6M from operating activities in the first half of 2025.

Guidance, Outlook, and Risks

• Lead Program Progress: The company initiated a confirmatory pharmacokinetic (PK) and pharmacodynamic (PD) study for its lead candidate, RLYB116 (a C5 inhibitor), in Q2 2025. Data is expected in Q3 and Q4 2025. RLYB116 targets immune platelet transfusion refractoriness and refractory antiphospholipid syndrome.
• Asset Sale (Subsequent Event): In July 2025, Rallybio entered an agreement to sell its interest in REV102 (an ENPP1 inhibitor) to a subsidiary of Recursion Pharmaceuticals. The deal includes an upfront equity payment of $7.5M, a contingent equity payment of $12.5M, and a $5.0M milestone cash payment.
• Liquidity Outlook: Management believes current resources ($45.7M) are sufficient to fund operations into the middle of 2027. However, the company anticipates needing substantial additional capital to complete development and commercialization of RLYB116.
• Listing Risk: The company received notice from Nasdaq on February 24, 2025, regarding non-compliance with the minimum $1.00 closing bid price requirement. Rallybio has until August 25, 2025, to regain compliance or risk delisting.
• Risk Factors: Key risks include the high probability of failure in clinical trials, the need for additional financing which may cause dilution, and the company's heavy dependence on the success of RLYB116.

Investor Verification Checklist

• Nasdaq Compliance: Verify if the stock price has sustained a $1.00 closing bid for 10 consecutive business days prior to August 25, 2025, to avoid delisting.
• RLYB116 Trial Data: Monitor the release of PK/PD data from the confirmatory study expected in late 2025 to assess the viability of the lead asset.
• Capital Requirements: Review the company's cash burn rate and the timeline for the next potential equity offering or debt financing given the $45.7M liquidity runway.
• REV102 Sale Closing: Confirm the closing of the asset sale to Recursion Pharmaceuticals and the receipt of the $7.5M upfront equity payment.
• Restructuring Costs: Track the completion of severance payments related to the 40% workforce reduction to ensure no unexpected future liabilities.